ACS chemical neuroscience molecule spotlight on fanapt

Research output: Contribution to journalShort surveypeer-review

6 Scopus citations


The new mixed dopamaine D2/serotonin 5-HT2A antagonist, Fanapt (iloperidone), was approved by the FDA on May 6th, 2009 for the treatment of schizophrenia in adults.

Original languageEnglish (US)
Pages (from-to)410
Number of pages1
JournalACS Chemical Neuroscience
Issue number6
StatePublished - Jun 16 2010
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on fanapt'. Together they form a unique fingerprint.

Cite this